Canada - inglese - Health Canada

alk-abello a/s - dolichovespula arenaria venom protein extract - powder for solution - 120mcg - dolichovespula arenaria venom protein extract 120mcg - allergenic extracts

Canada - inglese - Health Canada

alk-abello a/s - yellow hornet venom protein; white faced hornet venom protein; yellow jacket venom protein - powder for solution - 1.1mg; 1.1mg; 1.1mg - yellow hornet venom protein 1.1mg; white faced hornet venom protein 1.1mg; yellow jacket venom protein 1.1mg - allergenic extracts

Canada - inglese - Health Canada

alk-abello a/s - polistes spp venom protein extract - powder for solution - 1.1mg - polistes spp venom protein extract 1.1mg - allergenic extracts

Canada - inglese - Health Canada

alk-abello a/s - vespula spp venom protein extract - powder for solution - 1.1mg - vespula spp venom protein extract 1.1mg - allergenic extracts

Canada - inglese - Health Canada

alk-abello a/s - yellow jacket venom protein; yellow hornet venom protein; white faced hornet venom protein - powder for solution - 120mcg; 120mcg; 120mcg - yellow jacket venom protein 120mcg; yellow hornet venom protein 120mcg; white faced hornet venom protein 120mcg - allergenic extracts

Canada - inglese - Health Canada

alk-abello a/s - dolichovespula maculata venom protein extract - powder for solution - 1.1mg - dolichovespula maculata venom protein extract 1.1mg - allergenic extracts

Canada - inglese - Health Canada

jubilant hollisterstier llc - white faced hornet venom protein - powder for solution - 1300mcg - white faced hornet venom protein 1300mcg - allergenic extracts

Stati Uniti - inglese - NLM (National Library of Medicine)

novartis vaccines and diagnostics srl - neisseria meningitidis serogroup b nhba fusion protein antigen (unii: 28e911y7ae) (neisseria meningitidis serogroup b nhba fusion protein antigen - unii:28e911y7ae) - neisseria meningitidis serogroup b nhba fusion protein antigen 50 ug in 0.5 ml

Stati Uniti - inglese - NLM (National Library of Medicine)

merck sharp & dohme llc - haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen (unii: luy6p8763w) (haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen - unii:luy6p8763w) - haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen 7.5 ug in 0.5 ml - liquid pedvaxhib is indicated for routine vaccination against invasive disease caused by haemophilus influenzae type b in infants and children 2 to 71 months of age. liquid pedvaxhib will not protect against disease caused by haemophilus influenzae other than type b or against other microorganisms that cause invasive disease such as meningitis or sepsis. as with any vaccine, vaccination with liquid pedvaxhib may not result in a protective antibody response in all individuals given the vaccine. because of the potential for immune tolerance, liquid pedvaxhib is not recommended for use in infants younger than 6 weeks of age. (see precautions.) infants completing the primary two-dose regimen before 12 months of age should receive a booster dose (see dosage and administration). hypersensitivity to any component of the vaccine or the diluent. persons who develop symptoms suggestive of hypersensitivity after an injection should not receive further injections of the vaccine.

Stati Uniti - inglese - NLM (National Library of Medicine)

par pharmaceutical, inc. - tuberculin purified protein derivative (unii: i7l8fkn87j) (tuberculin purified protein derivative - unii:i7l8fkn87j) - tuberculin purified protein derivative 5 [iu] in 0.1 ml - tuberculin ppd is indicated as an aid in the detection of infection with mycobacterium tuberculosis . the standard tuberculin test employs the intradermal (mantoux) test using a 5 tu dose of tuberculin ppd.7 the 0.1 ml test dose of aplisol (tuberculin ppd, diluted) is equivalent to the 5 tu dose which has been clinically utilized and standardized with ppd-s. tuberculin skin testing is not contraindicated for persons who have been vaccinated with bcg and the skin-test results of such persons are used to support or exclude the diagnosis of m. tuberculosis infections.4 hiv infection is a strong risk factor for the development of tb disease in persons having tb infection. all hiv-infected persons should receive a ppd-tuberculin skin test.3 aplisol is contraindicated in patients with known hypersensitivity or allergy to aplisol or any of its components. aplisol should not be administered to persons who have previously experienced a severe reaction (e.g., vesiculation, ulceration, or necrosis) because of the sev